Published 2021
| Version v1
Publication
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
Creators
- Condorelli M.
- Bruzzone M.
- Ceppi M.
- Ferrari A.
- Grinshpun A.
- Hamy A. S.
- de Azambuja E.
- Carrasco E.
- Peccatori F. A.
- Di Meglio A.
- Paluch-Shimon S.
- Poorvu P. D.
- Venturelli M.
- Rousset-Jablonski C.
- Senechal C.
- Livraghi L.
- Ponzone R.
- De Marchis L.
- Pogoda K.
- Sonnenblick A.
- Villarreal-Garza C.
- Cordoba O.
- Teixeira L.
- Clatot F.
- Punie K.
- Graffeo R.
- Dieci M. V.
- Perez-Fidalgo J. A.
- Duhoux F. P.
- Puglisi F.
- Ferreira A. R.
- Blondeaux E.
- Peretz-Yablonski T.
- Caron O.
- Saule C.
- Ameye L.
- Balmana J.
- Partridge A. H.
- Azim H. A.
- Demeestere I.
- Lambertini M.
Contributors
Others:
- Condorelli, M.
- Bruzzone, M.
- Ceppi, M.
- Ferrari, A.
- Grinshpun, A.
- Hamy, A. S.
- de Azambuja, E.
- Carrasco, E.
- Peccatori, F. A.
- Di Meglio, A.
- Paluch-Shimon, S.
- Poorvu, P. D.
- Venturelli, M.
- Rousset-Jablonski, C.
- Senechal, C.
- Livraghi, L.
- Ponzone, R.
- De Marchis, L.
- Pogoda, K.
- Sonnenblick, A.
- Villarreal-Garza, C.
- Cordoba, O.
- Teixeira, L.
- Clatot, F.
- Punie, K.
- Graffeo, R.
- Dieci, M. V.
- Perez-Fidalgo, J. A.
- Duhoux, F. P.
- Puglisi, F.
- Ferreira, A. R.
- Blondeaux, E.
- Peretz-Yablonski, T.
- Caron, O.
- Saule, C.
- Ameye, L.
- Balmana, J.
- Partridge, A. H.
- Azim, H. A.
- Demeestere, I.
- Lambertini, M.
Description
Background: Knowledge is growing on the safety of assisted reproductive techniques (ART) in cancer survivors. No data exist, however, for the specific population of breast cancer patients harboring germline BRCA1/2 pathogenic variants. Patients and methods: This is a multicenter retrospective cohort study across 30 centers worldwide including women diagnosed at ≤40 years with stage I-III breast cancer, between January 2000 and December 2012, harboring known germline BRCA1/2 pathogenic variants. Patients included in this analysis had a post-treatment pregnancy either achieved through use of ART (ART group) or naturally (non-ART group). ART procedures included ovulation induction, ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection, and embryo transfer under hormonal replacement therapy. Results: Among the 1424 patients registered in the study, 168 were eligible for inclusion in the present analysis, of whom 22 were in the ART group and 146 in the non-ART group. Survivors in the ART group conceived at an older age compared with those in the non-ART group (median age: 39.7 versus 35.4 years, respectively). Women in the ART group experienced more delivery complications compared with those in the non-ART group (22.1% versus 4.1%, respectively). No other apparent differences in obstetrical outcomes were observed between cohorts. The median follow-up from pregnancy was 3.4 years (range: 0.8-8.6 years) in the ART group and 5.0 years (range: 0.8-17.6 years) in the non-ART group. Two patients (9.1%) in the ART group experienced a disease-free survival event (specifically, a locoregional recurrence) compared with 40 patients (27.4%) in the non-ART group. In the ART group, no patients deceased compared with 10 patients (6.9%) in the non-ART group. Conclusion: This study provides encouraging safety data on the use of ART in breast cancer survivors harboring germline pathogenic variants in BRCA1/2, when natural conception fails or when they opt for ART in order to carry out preimplantation genetic testing.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1074532
- URN
- urn:oai:iris.unige.it:11567/1074532
Origin repository
- Origin repository
- UNIGE